Herediter Meme Kanseri Yönetimi
Özet
Herediter meme kanseri, tüm meme kanserlerinin yaklaşık %10'unu oluşturan ve belirli patojenik gen mutasyonları ile nesilden nesle aktarılan önemli bir sağlık sorunudur. İlk kez 1866 yılında Pierre Paul Broca tarafından tanımlanan bu durum, 1990'larda Dr. Mary-Claire King’in BRCA1 ve BRCA2 genlerini keşfetmesiyle genetik bir temel kazanmıştır. Günümüzde DNA onarımında görevli BRCA1 ve BRCA2 gibi yüksek penetranslı tümör supresör genlerin yanı sıra TP53, PTEN, PALB2, CHEK2 ve ATM gibi orta ve yüksek penetranslı genlerin de bu kanser türüyle ilişkili olduğu bilinmektedir. Bu genlerdeki otozomal geçişli mutasyonlar, Knudson’un "çift vuruş" modeline göre kanserleşmeyi başlatır ve yatkınlık anne ile babadan eşit oranda aktarılır. Herediter kanser riskinin doğru yönetimi için tıbbi genetik uzmanları tarafından ayrıntılı anamnez alınarak soy ağacı (pedigri) oluşturulması, ardından Yeni Nesil Dizileme (NGS) gibi çoklu gen panelleriyle "germline" mutasyon analizi yapılması önerilmektedir. Test sonuçlarında karşılaşılan VUS (önemi belirsiz varyasyon) gibi durumlar uluslararası veri tabanları ile dinamik olarak takip edilmelidir. Yüksek riskli bireyler için 18 yaşından itibaren meme farkındalığı, düzenli klinik muayeneler, yıllık mamografi ve kontrastlı meme MRG'si ile tarama protokolleri uygulanır. Koruyucu yaklaşım olarak Tamoksifen gibi kemoprevensiyon ajanları veya risk azaltıcı bilateral mastektomi cerrahisi tercih edilebilirken, tüm süreç multidisipliner konseylerce yönetilmelidir.
Hereditary breast cancer accounts for approximately 10% of all breast cancers and is a significant health issue transmitted across generations through specific pathogenic gene mutations. First defined by Pierre Paul Broca in 1866, this condition gained a genetic basis in the 1990s with Dr. Mary-Claire King’s discovery of the BRCA1 and BRCA2 genes. Today, it is known that high-penetrance tumor suppressor genes involved in DNA repair, such as BRCA1 and BRCA2, as well as high and moderate-penetrance genes like TP53, PTEN, PALB2, CHEK2, and ATM, are associated with this cancer type. Autosomal dominant mutations in these genes initiate carcinogenesis according to Knudson’s "two-hit" model, with susceptibility transmitted equally from mothers and fathers. For the accurate management of hereditary cancer risk, it is recommended that medical geneticists establish a detailed pedigree through comprehensive history-taking, followed by "germline" mutation analysis using multi-gene panels like Next Generation Sequencing (NGS). Results such as VUS (Variants of Uncertain Significance) must be dynamically monitored via international databases. For high-risk individuals, screening protocols including breast awareness from age 18, regular clinical exams, annual mammography, and contrast-enhanced breast MRI are implemented. Preventive approaches may include chemoprevention agents like Tamoxifen or risk-reducing bilateral mastectomy, and the entire process must be managed by multidisciplinary tumor boards.
Referanslar
Krush AJ. Contributions of Pierre Paul Broca to cancer genetics. 1979.
Szabo CI, King M-C. Inherited breast and ovarian cancer. Human molecular genetics. 1995;4(suppl_1):1811-7.
Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences. 2010;107(28):12629-33.
Collins F, Lander E, Rogers J, Waterston R, Conso I. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931-45.
Stadler ZK, Thom P, Robson ME, Weitzel JN, Kauff ND, Hurley KE, et al. Genome-wide association studies of cancer. Journal of clinical oncology. 2010;28(27):4255.
Tucker T, Friedman J. Pathogenesis of hereditary tumors: beyond the “two‐hit” hypothesis. Clinical genetics. 2002;62(5):345-57.
King M-C, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-6.
Huber-Keener KJ. Cancer Genetics and Breast Cancer. Best Practice & Research Clinical Obstetrics & Gynaecology. 2022.
Yoshida R. Hereditary breast and ovarian cancer (HBOC): Review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer. 2021;28(6):1167-80.
Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. Journal of Clinical Oncology. 2002;20(6):1480-90.
Network NCC. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2022.
Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA oncology. 2021;7(2):230-7.
Silver EL, Niell-Swiller M. Should all patients undergoing genetic testing for hereditary breast cancer syndromes be offered a multigene panel? Current Opinion in Obstetrics and Gynecology. 2022;34(1):36-40.
Tan O, Shrestha R, Cunich M, Schofield D. Application of next‐generation sequencing to improve cancer management: A review of the clinical effectiveness and cost‐effectiveness. Clinical genetics. 2018;93(3):533-44.
Ge J, Eisenberg A, Budowle B. Developing criteria and data to determine best options for expanding the core CODIS loci. Investigative genetics. 2012;3(1):1-14.
Karantzali E, Rosmaraki P, Kotsakis A, Le Roux-Le Pajolec M-G, Fitsialos G. The effect of FBI CODIS Core STR Loci expansion on familial DNA database searching. Forensic Science International: Genetics. 2019;43:102129.
Oldt RF, Kanthaswamy S. Expanded CODIS STR allele frequencies–Evidence for the irrelevance of race-based DNA databases. Legal Medicine. 2020;42:101642.
Elrick A, Ashida S, Ivanovich J, Lyons S, Biesecker BB, Goodman MS, et al. Psychosocial and clinical factors associated with family communication of cancer genetic test results among women diagnosed with breast cancer at a young age. Journal of genetic counseling. 2017;26(1):173-81.
Armstrong J, Lynch K, Virgo KS, Schwartz MD, Friedman S, Dean M, et al. Utilization, timing, and outcomes of BRCA genetic testing among women with newly diagnosed breast cancer from a national commercially insured population: the ABOARD study. JCO Oncology Practice. 2021;17(2):e226-e35.
Yamauchi H, Takei J. Management of hereditary breast and ovarian cancer. International journal of clinical oncology. 2018;23(1):45-51.
Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, et al. Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline. Journal of Clinical Oncology. 2020;38(18):2080-106.
Trujillano D, Oprea GE, Schmitz Y, Bertoli‐Avella AM, Abou Jamra R, Rolfs A. A comprehensive global genotype–phenotype database for rare diseases. Molecular genetics & genomic medicine. 2017;5(1):66-75.
Network NCC. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. Version 1.2020. 2020.
Murphy BL, Yi M, Arun BK, Gutierrez Barrera AM, Bedrosian I. Contralateral risk-reducing mastectomy in breast cancer patients who undergo multigene panel testing. Annals of surgical oncology. 2020;27(12):4613-21.
Basu NN, Ross G, Evans D, Barr L. The Manchester guidelines for contralateral risk-reducing mastectomy. World Journal of Surgical Oncology. 2015;13(1):1-6.
Giannakeas V, Lim DW, Narod SA. The risk of contralateral breast cancer: a SEER-based analysis. British Journal of Cancer. 2021;125(4):601-10.
Hyder Z, Harkness EF, Woodward ER, Bowers NL, Pereira M, Wallace AJ, et al. Risk of contralateral breast cancer in women with and without pathogenic variants in BRCA1, BRCA2, and tp53 genes in women with very early-onset (< 36 Years) breast cancer. Cancers. 2020;12(2):378.
Hunt KK, Euhus DM, Boughey JC, Chagpar AB, Feldman SM, Hansen NM, et al. Society of Surgical Oncology Breast Disease Working Group statement on prophylactic (risk-reducing) mastectomy. Annals of surgical oncology. 2017;24(2):375-97.
